| [1] |
Khanna D, Khanna S, Khanna P, et al.Obesity: A Chronic Low-Grade Inflammation and Its Markers [J]. Cureus, 2022, 14(2): e22711.
|
| [2] |
Hausmann J, Waechtershaeuser A, Behnken I, et al. The role of adipokines in the improvement of diabetic and cardiovascular risk factors within a 52-week weight-loss programme for obesity [J]. Obes Res Clin Pract, 2019, 13(5): 440-447.
|
| [3] |
Zorena K, Jachimowicz-Duda O, Ślęzak D, et al. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications [J]. Int J Mol Sci, 2020, 21(10): 3570.
|
| [4] |
Jaberi SA, Cohen A, D’Souza C, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders [J]. Biomed Pharmacother, 2021, 142: 112002.
|
| [5] |
Krizanac M, Mass Sanchez PB, Weiskirchen R, et al. A scoping review on lipocalin-2 and its role in non-alcoholic steatohepatitis and hepatocellular carcinoma [J].Int J Mol Sci, 2021, 22(6): 2865.
|
| [6] |
Yan QW, Yang Q, Mody N,et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance [J]. Diabetes. 2007, 56(10): 2533-40.
|
| [7] |
Zhang W, Chen S, Zhuang X. Research Progress on Lipocalin-2 in Diabetic Encephalopathy [J]. Neuroscience. 2023, 515: 74-82.
|
| [8] |
Zhang Y, Foncea R, Deis JA, et al. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes [J]. PLoS One. 2014 May 12; 9(5): e96997.
|
| [9] |
Mosialou I, Shikhel S, Liu J-M, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2 [J]. Nature, 2017, 543(7645): 385-390.
|
| [10] |
Currò D, Vergani E, Bruno C, et al. Plasmatic lipocalin‐2 levels in chronic low‐grade inflammation syndromes: comparison between metabolic syndrome, total and partial adult growth hormone deficiency [J]. BioFactors, 2020, 46(4): 629-636.
|
| [11] |
Petropoulou PI, Mosialou I, Shikhel S, et al. Lipocalin-2 is an anorexigenic signal in primates [J]. ELife, 2020, 9: e58949.
|
| [12] |
Mosialou I, Shikhel S, Luo N, et al. Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes [J]. J Exp Med, 2020, 217(10): e20191261.
|
| [13] |
Wang X, Li H, Li W,et al. The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy [J]. Cell Biol Toxicol. 2020 Oct; 36(5): 437-457.
|
| [14] |
Su X, Zhou P, Qi Y. Down-regulation of LCN2 attenuates retinal vascular dysfunction and caspase-1-mediated pyroptosis in diabetes mellitus [J]. Ann Transl Med, 2022, 10(12): 695.
|
| [15] |
Wang H, Lou H, Li Y, et al. Elevated vitreous lipocalin-2 levels of patients with proliferative diabetic retinopathy [J]. BMC Ophthalmol, 2020, 20(1): 260.
|
| [16] |
Parmar T, Parmar VM, Perusek L, et al. Lipocalin 2 plays an important role in regulating inflammation in retinal degeneration [J]. J Immunol, 2018, 200(9): 3128-3141.
|
| [17] |
Gan J, Zheng Y, Yu QL, et al. Serum Lipocalin-2 Levels Are Increased and Independently Associated With Early-Stage Renal Damage and Carotid Atherosclerotic Plaque in Patients With T2DM [J]. Front Endocrinol (Lausanne), 2022, 13: 855616.
|
| [18] |
Bhusal A, Lee WH, Suk K. Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond [J]. Front Physiol. 2021, 12: 638112.
|
| [19] |
Bhusal A, Lee WH, Suk K. Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond [J].Front Physiol, 2021, 12: 638112.
|
| [20] |
Bhusal A, Rahman MH, Lee WH,et al. Paradoxical role of lipocalin-2 in metabolic disorders and neurological complications [J]. Biochem Pharmacol, 2019, 169: 113626.
|
| [21] |
Naudé PJ, Nyakas C, Eiden LE, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease [J]. FASEB J. 2012, 26(7): 2811-23.
|
| [22] |
Pinyopornpanish K, Phrommintikul A, Angkurawaranon C, et al. Circulating Lipocalin-2 level is positively associated with cognitive impairment in patients with metabolic syndrome [J]. Sci Rep, 2022, 12(1): 4635.
|
| [23] |
Rada P, González-Rodríguez á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? [J]. Cell Death Dis, 2020, 11(9): 802.
|
| [24] |
Lu J, Lin L, Ye C, et al. Serum NGAL Is Superior to Cystatin C in Predicting the Prognosis of Acute-on-Chronic Liver Failure [J]. Ann Hepatol, 2019, 18(1): 155-164.
|
| [25] |
Xu G, Wang YM, Ying MM, et al. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis [J]. Clin Mol Hepatol, 2021, 27(2): 329-345.
|
| [26] |
Asimakopoulou A, Fülöp A,Borkham-KamphorstE, et al. Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis [J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(9): 2093-2110.
|
| [27] |
Chen J, Lei S, Huang Y, et al. The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery [J]. Lipids Health Dis. 2022, 21(1): 10.
|
| [28] |
Shibata K, Sato K, Shirai R, et al. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments [J]. Heart Vessels. 2020, 35(7): 1012-1024.
|
| [29] |
Francisco V, Pino J, Gonzalez-Gay MA, et al. Adipokines and inflammation: is it a question of weight? [J]. Br J Pharmacol. 2018, 175(10): 1569-1579.
|
| [30] |
Cheng F, Ng NYH, Tam CHT, et al. Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS [J]. Endocr Connect, 2021, 10(10): 1243-1252.
|
| [31] |
Cakal E, Ozkaya M, Engin-Ustun Y, et al. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome [J]. J Endocrinol Invest, 2011, 34(2): 97-100.
|
| [32] |
Kruszewska J, Laudy-Wiaderny H, Kunicki M. Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients-The Debate Is Still Open [J]. Int J Environ Res Public Health, 2022, 19(4): 2099.
|